Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-06-19 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2023 annual profit distribution (dividend) plan approved at the 2024 shareholders' meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend distribution. It also references the shareholders' meeting resolution and related documents. The document is short (1889 characters) and primarily serves to inform shareholders about the dividend payment details rather than presenting a full financial report or detailed analysis. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2024-06-19 Chinese
关于子公司获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about its subsidiary receiving approval from a regulatory authority (国家药品监督管理局) for a chemical raw material drug listing application. It includes details about the approval notice, registration numbers, validity period, and risk warnings. The document is short (774 characters) and serves as a notification of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-03 Chinese
关于子公司获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about its subsidiary receiving approval from a regulatory authority (国家药品监督管理局) for a chemical raw material drug listing application. It contains no financial statements or detailed financial data, nor does it present a report or analysis. The document is short (711 characters) and serves as a notification of an event (approval notice) rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is an announcement of a regulatory approval event, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-24 Chinese
2023年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of 赛隆药业集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, profit distribution, amendments to company rules, and other governance matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5995 characters, which is sufficient for a detailed voting results announcement. Therefore, the correct classification is DVA with high confidence.
2024-05-16 Chinese
赛隆药业2023年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 Annual General Meeting (AGM) of a company. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document includes specific voting results on various proposals discussed at the AGM. It does not contain the full annual report or financial statements but focuses on the legal aspects and voting outcomes of the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is sufficient and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2024-05-16 Chinese
关于增加信息披露媒体的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (417 characters) from a company about adding new media outlets for information disclosure. It does not contain financial data, report content, or detailed management information. It is an official notice about disclosure practices, not a report or detailed filing. According to the rules, such short announcements about disclosure media are classified as Regulatory Filings (RNS).
2024-05-08 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.